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enteric fever in the United Kingdom 
has been seriously jeopardized. In 
cases of treatment failures, commonly 
used alternative antimicrobial agents 
have included third-generation ce-
phalosporins such as ceftriaxone. The 
macrolide antimicrobial azithromycin 
is also being increasingly used, par-
ticularly for patients with hypersen-
sitivity to penicillins (5). With this in 
mind, 50 S. Typhi and 40 S. Paratyphi 
A strains isolated from January 2005 
through December 2006, which ex-
hibited resistance to ciprofl oxacin at 
0.125 mg/L, were tested for resistance 
to azithromycin by Etest. Results in-
dicated that none of the isolates of S. 
Typhi exhibited MICs >8 mg/L, which 
corresponded to the MIC to azithromy-
cin of a drug-sensitive control strain 
of S. Typhi (range 4–8 mg/L, MIC90 
6 mg/L). For S. Paratyphi A, none 
of the isolates exhibited MICs >12 
mg/L, corresponding to that of a drug-
sensitive control strain of this serovar 
(range 6–12 mg/L, MIC90 10 mg/L). 
Although there are no defi nitive data 
on resistance levels for azithromycin 
in relation to treatment of typhoid and 
paratyphoid, these fi ndings suggest 
that resistance to this antimicrobial 
agent in terms of treatment effi cacy 
has not yet been jeopardized. 
These results indicate that the 
availability of effective antimicrobial 
agents for the treatment of typhoid 
and paratyphoid infection is becom-
ing increasingly limited for patients 
in the United Kingdom. Nevertheless, 
despite the dramatic upsurge in the oc-
currence of strains with decreased sus-
ceptibility, ciprofl oxacin still remains 
the drug of choice for many physi-
cians. It is reassuring that in cases of 
treatment failure, third-generation ce-
phalosporins such as ceftriaxone and 
macrolide antimicrobial agents such 
as azithromycin appear to be viable 
alternatives. 
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Usutu Virus 
Sequences in 
Culex pipiens 
(Diptera: Culicidae), 
Spain
To the Editor: Usutu virus 
(USUV) is an arbovirus and a member 
of the mosquito-borne cluster within 
the Flavivirus genus. USUV belongs 
to the Japanese encephalitis virus an-
tigenic group, which is closely related 
to pathogens such as West Nile virus 
(WNV) (1).
USUV has been isolated from a 
human in the Central African Repub-
lic and from several mosquito species 
from tropical and subtropical Africa 
(2). In late summer 2001, USUV 
emerged in central Europe and caused 
deaths in several species of resident 
birds in Austria (3). However, moni-
toring of USUV in dead birds from 
2003 through 2005 showed that the 
absolute numbers of USUV–associ-
ated bird deaths declined, although 
USUV detection persisted in bird tis-
sues (4). This decrease in USUV-as-
sociated bird deaths was attributed to 
herd immunity in the bird population 
(5). In the summer of 2005, USUV 
was detected in a blackbird in Hunga-
ry. The complete genomic sequence 
of the Hungarian USUV strain shared 
99.9% identity with the strain circu-
lating in Austria since 2001 (6). On 
the other hand, neutralizing antibod-
ies against USUV have been detected 
in sera of resident and migrant birds 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 5, May 2008 861 
Table. Incidence of resistance/decreased susceptibility to key antimicrobial agents in isolates of Salmonella enterica serovars Typhi 
and Paratyphi A, United Kingdom, 2001–2006* 
% S. Typhi resistant to % S. Paratyphi A resistant to 
Year No. studied C A Tm CpL CpH No. studied C A Tm CpL CpH
2001 170 24 23 23 35 0 232 28 27 27 23 2
2002 150 18 17 17 35 1 149 10 9 10 39 3
2003 218 20 20 21 43 1 177 17 18 17 65 12
2004 215 23 23 24 47 2 221 5 5 5 70 14
2005 222 29 29 29 62 2 217 7 7 7 60 12
2006 240 23 24 24 68 2 278 2 3 2 64 9
*C, chloramphenicol; A, ampicillin, Tm, trimethoprim, CpL, ciprofloxacin MIC 0.25–1.0 mg/L; CpH, ciprofloxacin MIC >1.0 mg/L. No isolates exhibited 
resistance to ceftriaxone or cefotaxime; of 50 S. Typhi and 40 S. Paratyphi A isolated in 2005 and 2006, the MIC to azithromycin by E test (AB Biodisk, 
Solna, Sweden) was not greater than 8 mg/L for S. Typhi and 12 mg/L for S. Paratyphi A, which corresponds to those of drug-sensitive controls of the 
respective serotypes. 
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in the United Kingdom without caus-
ing an obvious reduction in the bird 
population (7).
From May through October 2006, 
monitoring of fl aviviruses in mosqui-
toes was performed in the northeast 
region of Spain (Catalonia). This 
monitoring was implemented in the 3 
main wetlands of the region: Aigüa-
molls de la Empordà (Girona Prov-
ince) near France, where WNV was 
detected in dead horses in 2000 (8); 
Delta del Llobregat (Barcelona Prov-
ince); and Delta de l’Ebre (Tarragona 
Province). Mosquitoes were collected 
by mosquito control services in these 
areas. Female mosquitoes were classi-
fi ed and grouped in pools according to 
date, species, and localization. During 
this period, 436 pools belonging to 9 
mosquito species were collected. The 
most abundant species was Culex pipi-
ens (n = 168).
Viral RNA was recovered from 
mosquito pools by homogenization and 
viral RNA extraction with QIAamp Vi-
ral RNA Mini Kit (QIAGEN, Valencia, 
CA, USA), and then generic reverse 
transcription (RT)-nested PCR was 
used to identify fl aviviruses (9). This 
procedure was used to amplify a spe-
cifi c fragment of the NS5 gene within 
the fl avivirus genome. The 143-bp 
amplifi cation product was detected by 
electrophoresis and purifi ed by using 
QIAquick PCR Purifi cation Kit (QIA-
GEN). Sequencing reactions were 
performed with ABI Prism BigDye 
Terminator Cycle Sequencing v.3.1 
Ready Reaction (Applied Biosystems, 
Foster City, CA, USA), and analyzed 
by using an ABI PRISM model 3730 
automated sequencer (Applied Bio-
systems). Assembly of the consensus 
sequences and translation into amino 
acid sequences was performed with 
Larsergene DNASTAR group of pro-
grams (DNASTAR Inc., Madison, WI, 
USA). Comparisons with published 
sequences of known fl aviviruses were 
performed by searches with FASTA 
program in EMBL database (available 
from www.ebi.ac.uk/embl/) to iden-
tify the detected agent and to study the 
level of homology.
One pool of Cx. pipiens cap-
tured in the middle of August 2006 
from Delta del Llobregat, in a typical 
Mediterranean climate that contained 
3 female mosquitoes, was positive for 
fl aviviruses. That positive pool was 
obtained from the center of the village 
of Viladecans, where different com-
mon migratory and sedentary birds 
such as Passer domesticus, Hirundo 
rustica, or Delichon urbica feed and 
nest. The Spanish USUV sequence 
showed 97.97% homology to USUV 
strain SAAR-1776 from South Af-
rica; it showed 94.94% similarity 
with USUV strain Vienna 2001 from 
Austria and USUV strain Budgapest 
from Hungary, with 2-nt and 5-nt dif-
ferences, respectively (Figure). All 
of these were synonymous mutations 
and thus did not result in amino ac-
ids replacements. The homology data 
showed that the Spanish strain belongs 
to USUV species and is more related 
to the African USUV isolates than to 
central European isolates.
To date, no bird deaths observed 
in Barcelona Province have been as-
sociated with viral encephalitis. How-
ever, this region is where the USUV-
specifi c RT-PCR–positive samples 
were obtained from Cx. pipiens mos-
quitoes. One possible explanation for 
these fi ndings is that Spanish USUV 
could be naturally avirulent for birds 
because the African strains of USUV 
appear to be in Africa. Alternatively, 
USUV and other related viruses such 
as WNV may have been circulating 
in Spain for many years, as a result of 
regular reintroduction by birds migrat-
ing from Africa. Under such circum-
stances, natural genetic resistance, 
herd immunity, and cross-protective 
immunity caused by related viruses 
likely provided at least some protec-
tion against symptomatic infections. 
The discovery of USUV-specifi c RNA, 
most related to the African strains of 
USUV, in Cx. pipiens in Spain extends 
previous evidence (7,10) that USUV 
and related fl aviviruses such as WNV 
are being introduced into western Eu-
rope from Africa, presumably by mi-
gratory birds.
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Figure. Comparison at nucleotide level of sequenced fragment among related Usutu virus 
(USUV). Dot indicates coincident nucleotide. The partial nucleotide sequence of detected 
Spanish USUV has been deposited in the GenBank database under accession no. 
AM909649. S. Africa, South Africa.
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Rotavirus P[4]G2 
in a Vaccinated 
Population, Brazil
To the Editor: Gurgel et al. pro-
vide an early examination of postmar-
keting surveillance data from Brazil, 
one of the fi rst countries to implement 
routine childhood immunization with 
Rotarix vaccine (1). In a community 
with reported vaccination coverage of 
50%, the P[4]G2 strain was detected in 
all 21 rotavirus-positive stool samples 
identifi ed during November 2006–
February 2007. Although monitoring 
effectiveness of Rotarix against P[4]
G2 strains is of interest (2), the small 
sample size, short duration of surveil-
lance, and lack of a comparison group 
preclude fi rm assessment of an asso-
ciation between P[4]G2 predominance 
and vaccination.
Because Rotarix was introduced 
in Brazil in March 2006, most children 
>12 months old (66 [51%] of 129) in 
the study were ineligible for vaccina-
tion. Genotype P[4]G2 was the only 
strain identifi ed even in older children, 
which suggests either a change in dis-
ease ecology from vaccination or the 
random circulation of P[4]G2 strains 
in the community. Ongoing hospital-
based surveillance during 2006 in 3 
regional countries that had not intro-
duced rotavirus vaccine (El Salvador, 
Guatemala, and Honduras) showed 
that P[4]G2 was the predominant cir-
culating strain (prevalence 68%–81%). 
Thus, as previously documented (3,4), 
the predominance of P[4]G2 strains 
after Rotarix introduction in Brazil 
could represent a natural shift unre-
lated to vaccination.
Evaluation of vaccine effective-
ness against specifi c strains will allow 
full assessment of the public health 
impact of vaccination. Although the 
data are sparse in the study from Gur-
gel et al., a comparison of the odds of 
vaccination among rotavirus-positive 
(cases) versus rotavirus-negative 
(controls) children shows 80% vac-
cine effectiveness against P[4]G2 
strains among infants <1 year of age, 
in accordance with recently published 
data from a controlled trial (5). To 
further elucidate vaccine impact, we 
are providing support for vaccine ef-
fectiveness studies in Nicaragua and 
El Salvador and conducting strain 
monitoring before and after licensure 
throughout Latin America.
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Letters
Letters commenting on recent articles as 
well as letters reporting cases, outbreaks, 
or original research are welcome. Letters 
commenting on articles should contain no 
more than 300 words and 5 references; they 
are more likely to be published if submit-
ted within 4 weeks of the original article’s 
publication. Letters reporting cases, out-
breaks, or original research should contain 
no more than 800 words and 10 references. 
They may have one Figure or Table and 
should not be divided into sections. All let-
ters should contain material not previously 
published and include a word count.
